Stockscreener 앱 받기
22.63
9.38%
1.94
시장 영업 전:
23.32
0.69
+3.05%
Aktis Oncology Inc 주식(AKTS)의 최신 뉴스
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Raymond James initiates Aktis Oncology stock coverage with buy rating By Investing.com - Investing.com Canada
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - AOL.com
Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday - Benzinga
Aktis Oncology: Mini-Proteins With A Targeted Punch (NASDAQ:AKTS) - Seeking Alpha
AKTS: Advancing novel radiopharmaceuticals with strong early data, robust supply, and pipeline growth - TradingView
H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $35 - Moomoo
H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $35 - Moomoo
AKTS Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
AKTS Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressGrowth Acceleration Report - newsline.com
Aktis Oncology CEO to present new targeted radiopharmaceuticals at Jefferies Healthcare Conference - Pluang
Aktis Oncology to Present at the Jefferies Global Healthcare Conference - The Manila Times
a16z Capital Management, L.L.C.'s Aktis Oncology Inc(AKTS) Holding History - GuruFocus
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance
Top Premarket Gainers - Moomoo
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors - The Manila Times
Aktis Oncology reports promising first-in-human... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting - Quiver Quantitative
Aktis Oncology Reports First-in-Human Clinical Imaging and - GlobeNewswire
New cancer agent shows high tumor uptake, limited healthy exposure - Stock Titan
Top Cybin (HELP) Competitors 2026 - MarketBeat
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Blue Owl discloses 5.92% stake in Aktis Oncology (AKTS) in Schedule 13G - Stock Titan
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool
AKTS: Advancing miniprotein radioconjugates for cancer, with strong pipeline, partnerships, and cash runway - TradingView
AKTS: Miniprotein radiopharmaceuticals advance in oncology with strong clinical and financial momentum - TradingView
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
TD Cowen Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
Aktis: Q1 Earnings Snapshot - 10TV
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - The Manila Times
Aktis Oncology Q1 net loss widens on increased IPO-related expenses - TradingView
Aktis Oncology (NASDAQ: AKTS) boosts cash to $538.5M after IPO despite higher Q1 loss - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aktis Oncology (NASDAQ: AKTS) boosts cash with IPO, posts wider Q1 loss - Stock Titan
Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q1 Revenue $3.2M - Moomoo
Cancer radiopharma firm Aktis adds $365M IPO cash, funds to 2029 - Stock Titan
Aktis Oncology to Present at the BofA Securities Health Care Conference - GlobeNewswire
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer By Investing.com - Investing.com India
Aktis Oncology CEO to present new targeted radiopharmaceuticals at BofA Health Care Conference - Pluang
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead - TradingView
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors - MarketBeat
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer - Investing.com
Aktis opens prostate cancer study as it broadens AKY-2519 testing - Stock Titan
Aktis Oncology Initiates Phase 1b Clinical Trial for - GlobeNewswire
UCB strikes up to $2.2B Candid deal, spotlighting Two River and Vida - Stock Titan
1.27%
1.43%
자본화:
|
볼륨(24시간):